Efficacy and Safety of Ciprofol versus Propofol for Tracheal Intubation in Pediatric Patients Undergoing Laparoscopic Hernia Repair: An Assessor-Blinded Randomised Controlled Trial Authors: Jieze Pan, Tianhao Zhong, Yiwen Lv, Miao Jiang, Lijie Fang, Xuhui Cui, Jie Wang, Ruifeng Zeng Published: 2026 ABSTRACT AbstractBackgroundCiprofol, a novel GABAA receptor agonist, might be an alternative for pediatric anesthesia. This study aimed to determine the ED95 of ciprofol, and compare its efficacy and safety with propofol for tracheal intubation in pediatric patients undergoing laparoscopic hernia repair.Patients and MethodsOf 166 screened children, 120 were enrolled: 40 patients to dose-finding phase to determine the ED95 of ciprofol by biased coin design up-and-down sequential method, and the remaining 80 patients to non-inferiority comparison phase. 80 patients were randomly allocated in 1:1 ratio to receive ciprofol (0.782 mg/kg) or propofol (4 mg/kg) for induction, combined with fentanyl and cisatracurium. Primary outcome was proportion of patients who achieved an excellent grade for tracheal intubation conditions. Secondary outcomes included incidence of adverse events, hemodynamic parameters, loss of consciousness time, and PACU recovery time.Results(1) ED95 of ciprofol for tracheal intubation in children undergoing laparoscopic hernia repair was 0.782 mg/kg (95% CI: 0.75–0.795 mg/kg). (2) An excellent grade for tracheal intubation conditions was achieved in 38 (95.0%) children in ciprofol group versus 35 (89.7%) children in propofol group in per-protocol analysis (rate difference 5.3%, 95% CI −4.14–14.73%). In intention-to-treat analysis, excellent grade rate in propofol group was 90.0% (36/40), with a rate difference of 5.0% (95% CI −4.1%–14.9%). Non-inferiority of ciprofol to propofol was confirmed in both analyses. Adverse events occurred in 7 (17.5%) children receiving ciprofol and 30 (76.9%) receiving propofol. Injection pain was significantly lower with ciprofol (2.5% vs. 38.5%).ConclusionIn healthy, non-obese children aged 3–6 years undergoing laparoscopic hernia repair, ED95 of ciprofol for tracheal intubation was 0.782 mg/kg. Ciprofol (0.782 mg/kg) demonstrated non-inferiority to propofol (4 mg/kg) in excellent tracheal intubation conditions, with lower injection pain and more stable hemodynamics.Keywords: pediatric anesthesia, ciprofol, tracheal intubation, 95% effective dose, propofol Introduction In pediatric anesthesiology, identifying the ideal anesthetic agent remains a key objective.1 Such an agent should combine rapid onset and emergence, a wide therapeutic index, and minimal adverse effects.2 Propofol has long been regarded as the gold standard in this setting. However, its use is limited by a high incidence of injection pain and dose-dependent cardiovascular depression.3,4 Therefore, there is an urgent need to identify a more ideal anesthetic agent for pediatric patients. Ciprofol (HSK3486) is a novel sedative agent that acts as a gamma-aminobutyric acid A (GABAA) receptor agonist.5,6 Although its mechanism is similar to that of propofol, the introduction of a cyclopropyl group into its structure confers enhanced spatial selectivity and binding affinity, resulting in a potency four to five times greater than that of propofol.5,7 Moreover, previous studies also suggest a potentially superior safety profile: evidence from adult clinical settings—including procedural sedation, general anesthesia induction, and ICU sedation—consistently indicates that ciprofol provides a comparable sedative effect to propofol, with a lower incidence of adverse events such as injection pain and more stable hemodynamics.8–12 These advantages position ciprofol as a promising alternative to propofol. Although extensive studies in adults have demonstrated the advantages of ciprofol in sedation and anesthesia, high-quality evidence regarding its efficacy and safety in pediatric patients remains scarce, highlighting the necessity for dedicated pediatric research. Tracheal intubation is the preferred approach for airway management during laparoscopic surgery due to its enhanced safety and lower incidence of aspiration.13 Although a previous dose-finding study determined the median effective dose of ciprofol for laryngeal mask insertion in children,14 the effective dose for pediatric tracheal intubation has not been established. Moreover, no randomized controlled trials have yet compared ciprofol with propofol in children undergoing tracheal intubation. Therefore, we conducted this prospective, randomized, assessor-blind, non-inferiority trial to investigate the effective dose of ciprofol for tracheal intubation, and whether ciprofol is non-inferior to propofol in achieving an excellent grade for tracheal intubation conditions in healthy children aged 3–6 years undergoing laparoscopic hernia repair, thereby providing clinical guidance for pediatric anesthesia. Materials and Methods Study Design and Ethical Approval This prospective, randomized, assessor-blind, non-inferiority clinical trial was conducted in the Department of Anesthesiology and Perioperative Medicine at the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University from March 2025 to September 2025. The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University (Approval Number 2025-K-02-01) and registered with the Chinese Clinical Trial Registry (Registration Number ChiCTR2500098764). The clinical trial adheres to the Declaration of Helsinki, the Good Clinical Practice (GCP) guidelines issued by the State Drug Administration (SDA), and other relevant regulations. Prior to any study-related procedures, written informed consent was obtained from a parent or legal guardian of each participant. Dose-Finding Study of Ciprofol for Tracheal Intubation in Pediatric Patients Using a Biased Coin Up-and-Down Sequential Design This prospective dose-finding trial employed a biased coin design up-and-down sequential method (BCD-UDM)15,16 to determine the 95% effective dose (ED95) of ciprofol for achieving an excellent grade for tracheal intubation in non-obese children aged 3–6 years undergoing elective laparoscopic hernia repair under general anesthesia. The participant flow is detailed in Figure 1. Based on preliminary data and existing literature,17 the initial dose of ciprofol was set at 0.6 mg/kg, with a dose adjustment gradient of 0.05 mg/kg. The dose for each subsequent patient was determined according to the intubation response of the preceding patient, using a BCD-UDM algorithm implemented in R statistical software (Γ=0.95). The tracheal intubation response — defined as coughing during intubation or an increase in mean arterial pressure (MAP) or heart rate (HR) >20% from baseline within 2 minutes after intubation—was considered ineffective. If the preceding dose was ineffective, the dose for the next patient was increased by 0.05 mg/kg. Conversely, if the dose was effective (no positive responses), the subsequent dose was randomly assigned: with a 5% probability [b= (1−Γ)/Γ=0.05] it was decreased by 0.05 mg/kg, and with a 95% probability (1−b=0.95) that it would remain unchanged. Regarding sample size, due to the non-independence of data obtained from dose-finding studies using the biased coin design up-and-down method and the unknown underlying distribution, conventional sample size calculation formulas are not fully applicable. Previous simulation studies have shown that enrolling 20 to 40 subjects can yield reliable dose estimates under most circumstances.18 The ED95 of ciprofol for effectively suppressing the tracheal intubation response in this pediatric population was estimated using isotonic regression and 95% confidence intervals (CI) were obtained from 2000 bootstrap replications. Study flow diagram of participants in the dose-finding phase of ciprofol for tracheal intubation in pediatric patients. Sample Size Calculation for Randomized Controlled Trial Sample size calculation was performed using PASS 2021 (NCSS, LLC, Kaysville, USA). Based on pilot data, the proportion of patients achieving an excellent grade for intubation conditions was 98% in the ciprofol group and 91% in the propofol group. With a one-sided test level α=0.025, power (1 – β)=0.8, and a non-inferiority margin δ=−8%, the calculated sample size was 72 patients. Considering a potential 10% dropout rate, the final sample size was adjusted to 80 patients. Patient Enrollment Of the 166 children screened, 120 met the eligibility criteria and were enrolled in this study. These children were aged 3–6 years, scheduled for elective laparoscopic hernia repair under general anesthesia, with the American Society of Anesthesiologists (ASA) Physical Status class of I or II and body mass index (BMI) in the 25th to 85th percentile range.19 This study was designed as a two-phase trial: a dose-finding phase to estimate the 95% effective dose (ED95) of ciprofol, followed by a confirmatory non-inferiority phase that used the estimated ED95 to compare ciprofol with propofol. Among them, 40 patients were assigned to the dose-finding phase to determine the ED95 of ciprofol, while the remaining 80 patients were allocated to the subsequent non-inferiority comparison phase versus propofol. Primary exclusion criteria included anticipated difficult airway, acute upper respiratory tract infection, uncontrolled asthma, major comorbidities (eg, cardiomyopathy, hepatic, renal dysfunction), recent use of sedative-hypnotics (including benzodiazepines and barbiturates) within 7 days prior to surgery, allergy to study-related components including ciprofol and opioids, and obesity or underweight as defined by age-specific body mass index percentile. Randomization and Blinding Prior to enrollment, an independent statistician generated the randomization sequence in a 1:1 ratio using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). The group assignments were sealed in sequentially numbered, opaque envelopes to ensure allocation concealment. An anesthesiologist not involved in the study subsequently opened each envelope immediately prior to anesthetic induction. While the physical properties of the two drugs precluded blinding of the administering anesthesiologist, full blinding was maintained for the anesthesiologist responsible for tracheal intubation and clinical evaluations, and for the data statistician during the entire study period. Anesthesia Management Participants were randomly assigned to either the ciprofol group or the propofol group. Anesthetic induction was performed using 4 mg/kg propofol20,21 or the ED95 of ciprofol calculated based on the first part of this study, combined with 0.1 mg/kg cisatracurium and 2 µg/kg fentanyl. Prior to surgery, all patients adhered to the standard preoperative fasting guidelines,22 abstaining from solid food for at least 8 hours and from clear fluids for 2 hours. After establishing adequate peripheral venous access in the operating room, an intravenous infusion of lactated Ringer’s solution was initiated. Standard monitoring was applied throughout, including electrocardiogram (ECG), non-invasive blood pressure (NIBP), peripheral pulse oxygen saturation (SpO2), and Bispectral Index (BIS). Baseline vital signs were recorded as the average of three consecutive measurements taken after the patient was placed in the supine position. Before anesthesia induction, patients underwent preoxygenation via a face mask at a flow rate of 5 L/min for 3 minutes. Subsequent to preoxygenation, intravenous anesthesia induction was administered. Patients in the ciprofol group received the ED95 of ciprofol (Ciprofol Injection, Liaoning Chengdu Hisco Pharmaceutical Co., Ltd.) administered over 25 ± 5 seconds, whereas those in the propofol group received 4 mg/kg of propofol (Propofol Injection, Beijing Fresenius Kabi Pharmaceutical Co., Ltd). Injection pain was evaluated using the four-point scale of Ambesh following administration (Table S1). The Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) scale (Table 1) was used to evaluate loss of consciousness.23,24 Once the MOAA/S score of ≤1 was attained, 0.1 mg/kg of cisatracurium besylate and 2 µg/kg of fentanyl were administered sequentially. When the BIS value decreased to ≤50, tracheal intubation was performed by a blinded and experienced pediatric anesthesiologist. This anesthesiologist had independently completed over 200 pediatric tracheal intubation procedures. The time limit for a single intubation attempt was 30 seconds, with a maximum of three attempts by the same operator. In the event of intubation failure, supraglottic airway device ventilation or mask ventilation was used; if ventilation remained impossible, an emergency front-of-neck airway was established, and every effort was made to maximize the possibility of successful oxygenation. Intubation conditions were evaluated using the Helbo-Hansen modified score (Table S2).25 After intubation, anesthesia was maintained with 3% sevoflurane in 60% oxygen at a fresh gas flow of 2 L/min. Table 1Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) ScaleScoreResponsiveness5Responds readily to name spoken in normal tone4Lethargic response to name spoken in normal tone3Responds only after name is called loudly and/or repeatedly2Responds only after mild prodding or shaking1Responds only after painful trapezius squeeze0Does not respond to painful trapezius squeeze Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) Scale Data Collection and Outcome Assessment Baseline characteristics—including gender, age, height, weight, BMI, HR, MAP, and BIS value—were recorded before operation (T0). MAP, HR, and BIS values were documented at the following time points: 30 seconds after induction (T1), immediately before intubation (T2), immediately after intubation (T3), and 5 minutes after intubation (T4). Anesthetic depth was assessed using BIS monitoring combined with the MOAA/S score. The primary outcome was the proportion of patients who achieved an excellent grade for intubation conditions on the first attempt. Secondary outcomes included the incidence of adverse events, hemodynamic parameters (HR and MAP), loss of consciousness time, and postoperative recovery time in the post-anesthesia care unit (PACU). Recovery time was defined as the time from the patient’s arrival in the PACU until discharge from the PACU. The Aldrete modified score was used to assess the patients, and they were allowed to leave the PACU when the score was ≥9. Specifically, adverse events included hypotension (mean arterial pressure decrease >30% from the baseline lasting for at least two minutes), injection pain, body movement, hypoxemia (oxygen saturation <92% for >10s), bradycardia (HR<80 beats min−1), and nausea and vomiting. Statistical Analysis Statistical analyses were performed using IBM SPSS Statistics for Windows version 27.0 (SPSS Inc., Chicago, IL, USA) and R software (R Foundation for Statistical Computing, Vienna, Austria). The Shapiro–Wilk test was applied to assess data normality. Normally distributed quantitative data are presented as Mean ± Standard Deviation, while skewed quantitative data are summarized as median and interquartile range (IQR). Categorical variables are reported as frequencies and percentages. The primary outcome was analyzed using both per-protocol (PP) and intention-to-treat (ITT) populations. The PP population included patients who completed the study without major protocol violations. The ITT population included all randomized patients, and the analysis was based on the observed outcomes as no primary outcome data were missing. Non-inferiority analysis was evaluated using a one-sided Z-test for the difference in proportions, with a 95% confidence interval (CI) calculated for the difference between groups. Non-inferiority was established if the lower bound of the CI exceeded −8%. Intergroup comparisons were performed using independent samples t-test, chi-square test, Mann–Whitney U-test, as appropriate. The p-value <0.05 was considered statistically significant. Results Between March and September 2025, a total of 166 children were screened for eligibility and 120 pediatric patients were eventually enrolled. Of these, 40 patients were enrolled in the dose-finding phase for determining the ED95 of ciprofol. The sequential dose allocation and response outcomes are illustrated in Figure 2. Using the biased coin design up-and-down method (BCD-UDM), the ED95 of ciprofol was determined via isotonic regression to be 0.782 mg/kg (95% confidence interval [CI]: 0.75–0.795 mg/kg). Data of the sequential up-and-down responses of ciprofol. The starting dose is 0.6 mg/kg, and the dose increment is 0.05 mg/kg. Orange solid dots represent successful tracheal intubation (negative intubation response), whereas blue solid dots represent failed intubation (positive intubation response). The remaining 80 participants who met the inclusion criteria were enrolled and randomly assigned to one of two groups. One patient from the propofol group was excluded due to conversion from laparoscopic to open surgery, resulting in 79 patients included in the per-protocol (PP) analysis (ciprofol group: n=40; propofol group: n=39). This excluded patient had achieved an excellent grade for tracheal intubation conditions. The participant flow is detailed in Figure 3. Demographic characteristics and baseline hemodynamic parameters were comparable between the two groups, with no statistically significant differences observed (Table 2). Study flow diagram of participants in the non-inferiority comparison phase. Table 2Baseline Characteristics of Pediatric PatientsParameterCiprofol GroupPropofol GroupP valueSample sizen=40n=39–Gender (Male/Female)31/933/60.420Age (years)4 (3–5)4 (3–5)0.805Height (cm)108.6±11.1107.1±8.60.522Weight (kg)17.1 (15–21)17.0 (15–19)0.658Body Mass Index (kg/m2)15.2±1.615.0±1.40.733Heart Rate (beat per minute)98.6±13.2101.8±11.90.247Mean Arterial Pressure (mmHg)74.2±10.778.5±10.20.073Bispectral Index97 (95–98)97 (95–98)0.742Surgical Duration (min)23 (22–23.7)23 (22–24)0.271Anesthesia Duration (min)38.3±10.239.8±8.20.463Notes: Values are median (IQR [range]), number or mean (SD). Baseline Characteristics of Pediatric Patients Notes: Values are median (IQR [range]), number or mean (SD). Figure 4 shows the primary outcome non-inferiority analyses. In the PP analysis, the proportion of patients achieving an excellent grade for tracheal intubation conditions was 95.0% (38/40) in the ciprofol group and 89.7% (35/39) in the propofol group (rate difference 5.3%; 95% CI: –4.14% to 14.73%). In the intention-to-treat (ITT) analysis, which included all 40 randomized patients in each group, the excellent rate in the propofol group was 90.0% (36/40), yielding a rate difference of 5.0% (95% CI: –4.1% to 14.9%). Both analyses demonstrated non-inferiority of ciprofol to propofol, as the lower limits of the confidence intervals were above the pre-specified non-inferiority margin of −8%.26 Rate difference (95% CI) of an excellent grade for tracheal intubation conditions in children receiving either ciprofol or propofol. The non-inferiority margin was set at −8%. Secondary outcomes are summarized in Table 3. The overall incidence of adverse events was 17.5% (7 cases in 40 patients) in the ciprofol group and 76.9% (30 cases in 39 patients) in the propofol group. Specifically, significant differences were observed in the incidence of injection pain (2.5% vs. 38.5%, P<0.001) and hypotension (10.0% vs. 28.2%, P=0.039). With regard to injection pain (Table S3), 2 patients in the ciprofol group experienced mild pain, whereas the propofol group included 11 cases of severe pain, 3 of moderate pain, and 1 of mild pain. Neither group exhibited hypoxemia, nausea, or vomiting. Furthermore, no patient reported recall of the surgical procedure. Table 3Secondary Outcomes of Children Receiving Ciprofol or PropofolPropofol GroupCiprofol Groupχ2 ValueP ValueTotal30 (76.9%)7 (17.5%)––Hypotension11 (28.2%)4 (10%)4.260.039Injection pain15 (38.5%)1 (2.5%)13.09<0.001Body movement4 (10.3%)1 (2.5%)–0.201+Hypoxemia00––Bradycardia01 (2.5%)–1+Nausea and vomiting00––Notes: Values are number (proportion). A value of p < 0.05 was considered to indicate statistical significance; “+”: Fisher’s exact test (two-tailed); “-”: P value was not calculated, as no events occurred in either group. Secondary Outcomes of Children Receiving Ciprofol or Propofol Notes: Values are number (proportion). A value of p < 0.05 was considered to indicate statistical significance; “+”: Fisher’s exact test (two-tailed); “-”: P value was not calculated, as no events occurred in either group. Hemodynamic and BIS trends at different time points are presented in Figure 5. In the propofol group, significant increases in both heart rate and mean arterial pressure were observed after tracheal intubation, with the differences showing statistical significance (p<0.001). In contrast, the ciprofol group exhibited minimal changes in heart rate and mean arterial pressure during the same period, and these changes were not statistically significant. Comparison of Ciprofol versus Propofol on Relevant Parameters. (A) Mean arterial pressure (MAP); (B) Heart rate (HR); (C) Bispectral index (BIS); Data are presented as mean ± standard deviation (SD); *** indicates significant differences in HR between T2 and T3 within the Propofol Group (P<0.001); # indicates significant differences in HR between the Propofol Group and the Ciprofol Group at T3 (P<0.05). No significant difference was observed between T2 and T3 within Ciprofol Group. For all other time points, no statistically significant differences were observed between the two groups in HR, MAP, or BIS. As shown in Table S4, the time to loss of consciousness (MOAA/S≤1) was slightly longer in the ciprofol group than in the propofol group (44.8 s vs. 36.1 s, P<0.01). In contrast, no statistically significant difference was observed in PACU recovery time between the two groups (35 min vs. 33 min, P=0.894), indicating comparable recovery profiles. Discussion This randomized controlled trial comparing the efficacy and safety of ciprofol versus propofol for tracheal intubation demonstrated that ciprofol is non-inferior to propofol in achieving an excellent grade for tracheal intubation conditions in pediatric patients aged 3–6 years, while offering a significantly improved safety profile. Our outcomes highlight ciprofol’s potential as a new drug for anesthesia induction in pediatric surgery, supported by its comparable sedative efficacy and reduced incidence of adverse events compared to propofol. The consistency between the per-protocol and intention-to-treat analyses further supports the robustness of this non-inferiority conclusion. It is well known that developmental variability in children significantly influences drug metabolism. Age-dependent changes in body composition, organ function, and enzyme activity collectively affect both pharmacokinetic and pharmacodynamic profiles.27 This is reflected in the dosing differences between adults and children: the recommended induction dose of ciprofol in adults is 0.4 mg/kg, and children may generally require a higher dose for general anesthesia induction.28 Although ciprofol exhibits lower lipid solubility than propofol, the comparable PACU recovery times observed in our study indicate that the difference in redistribution half-lives between the two agents did not prolong PACU recovery times in the context of short procedures. Nevertheless, the interaction between ciprofol’s lipophilicity, redistribution, and recovery time merits further investigation. Specifically, future research should focus on developing population pharmacokinetic models that incorporate developmental covariates (such as age, weight, and body composition) to facilitate individualized dosing and the establishment of age-specific dosage formulas. Such efforts would help ensure the efficacy and safety of ciprofol throughout pediatric development. Tracheal intubation constitutes a highly stimulating procedure in pediatric patients. Accordingly, in determining the induction dose of propofol, this study selected a comparatively high dose (4 mg/kg), based on clinical experience and previous evidence, which remains within the recommended range according to the prescribing information. However, as illustrated in Figure 5, the propofol group still exhibited considerable fluctuations in heart rate and mean arterial pressure during intubation. In contrast, such hemodynamic variability was markedly attenuated in the ciprofol group, with no statistically significant changes over time. These findings further highlight the favorable profile of ciprofol in providing excellent grade tracheal intubation conditions. Injection pain is one of the most frequently reported and distressing adverse effects of propofol in patients, especially in pediatric patients.29 It exacerbates preoperative anxiety and contributes to negative perioperative experiences.30,31 The underlying mechanism is thought to be multifactorial, possibly related to the high concentration of free drug in the aqueous phase of the fat emulsion and direct irritation of the venous endothelium.31 Previous studies have concluded that ciprofol significantly reduces injection pain in diverse adult populations, which is consistent with its pharmacological profile.32–34 Our study provides new evidence that ciprofol offers a particular advantage in the pediatric population. This advantage may be attributed to its higher potency, enabling equivalent anesthetic effects at lower doses. It is hypothesized that the innovative introduction of a cyclopropyl structure may significantly enhance the water solubility of ciprofol, thereby potentially reducing pain associated with fat emulsions.35 However, the exact mechanism underlying this difference remains unclear. These proposed mechanisms should be interpreted as speculative and require confirmation through dedicated pharmacokinetic and pharmacodynamic studies. Beyond improved injection tolerance, ciprofol also demonstrated superior hemodynamic stability. A markedly lower incidence of hypotension was observed in the ciprofol group, suggesting a more moderate effect on blood pressure while maintaining adequate anesthetic depth, which aligns with previous studies.36,37 Propofol-induced hypotension involves multiple mechanisms, including reduced myocardial contractility through decreased intracellular free Ca2⁺ concentration in cardiomyocytes, vasodilation via sympathoinhibition, and reduced vascular smooth muscle tone, leading to decreased venous return and cardiac preload, and consequently reduced cardiac output.38 As a structural analog of propofol, ciprofol may share some of these pathways; however, the cyclopropyl modification may enhance its stereoselectivity toward GABAA receptors, potentially contributing to its more stable hemodynamic profile.39–42 Further mechanistic studies are warranted to substantiate the specific molecular basis of these clinical observations. In our study, the onset time of ciprofol was slightly longer than that of propofol (44.8 s vs. 36.1 s). This result differs from the shorter onset times reported by Zhu et al43, a discrepancy that may be attributed to differences in drug dosage, infusion rate, and patient characteristics.27 The study by Zhu et al was conducted in adults, whereas the 8.7-second difference observed in our study could be partly related to physiological differences between adult and pediatric patients. Although the difference was statistically significant, in clinical practice it does not appear to have affected airway management or surgical preparation. Nevertheless, recovery times in the PACU were similar between the two groups, indicating no delay in emergence. The sedative mechanisms of ciprofol and propofol are similar: both potentiate GABAergic transmission, which induces neuronal hyperpolarization and reduces central nervous system excitability, thereby resulting in rapid loss of consciousness.27 Additionally, ciprofol exhibits a high protein binding rate, resulting in relatively lower concentrations of free, biologically active drug.35 Given that this finding was obtained from a relatively small sample size, whether this difference reflects a true pharmacological effect or is attributable to sampling error remains to be determined. Larger-scale studies in pediatric populations are needed to further clarify whether an onset difference exists. These observations warrant further pharmacokinetic investigations in pediatric patients to fully elucidate the underlying mechanism. Several limitations of this study should be acknowledged. First, the assessor-blind design may introduce potential bias, although this was mitigated by strict allocation concealment. Specifically, the anesthesiologist responsible for tracheal intubation and clinical assessment, as well as the data statistician, remained blinded throughout the study, while only the anesthesiologist administering the drug was aware of group allocation, thereby minimizing the risk of bias. Second, our study population was restricted to healthy, non-obese children aged 3–6 years with ASA physical status I or II who underwent elective short laparoscopic hernia repair at a single center. Consequently, the findings of this study apply specifically to this population and should not be overgeneralized to other pediatric age groups, obese children, those with higher ASA classifications, or different surgical settings. The estimated ED95 should not be regarded as a standard pediatric dose of ciprofol. Further studies are needed to evaluate the efficacy and safety of ciprofol in these broader populations. Third, a fixed drug dosage was used in our study, and future research should explore a broader dosing range or target-controlled infusion protocols to further optimize ciprofol-based induction for pediatric anesthesia. Conclusion This study determines the ED95 of ciprofol in pediatric patients to be 0.782 mg/kg, and demonstrates preliminary evidence on the efficacy and safety of ciprofol as an induction agent for tracheal intubation in pediatric patients. Specifically, in healthy, non-obese children aged 3–6 years undergoing elective laparoscopic hernia repair, ciprofol was non-inferior to propofol in achieving an excellent grade for intubation conditions, with significantly reduced injection pain and more stable hemodynamics. These advantages position ciprofol as a potential alternative anesthetic agent for pediatric anesthesia. Future studies should aim to validate these results in more diverse pediatric populations, and explore the development of pharmacokinetic models to support individualized dosing strategies. Acknowledgments The authors would like to express their sincere gratitude to all children, and the staff of the Department of Pediatric Surgery and the Operating Room at the Second Affiliated Hospital of Wenzhou Medical University and Yuying Children’s Hospital for their invaluable guidance and support throughout this study. Funding Statement This study was financially supported by Basic Public Welfare Research Project of Zhejiang Province (LGD20H090003) and Basic Public Welfare Research Project of Wenzhou City (Y20220945). Data Sharing Statement The datasets generated and analyzed during the current study are available from the corresponding author, Ruifeng Zeng, upon request. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author, Ruifeng Zeng, upon request.